Safety and Efficacy of Bivalirudin Monotherapy in Patients With Diabetes Mellitus and Acute Coronary SyndromesA Report From the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Trial
Frederick Feit, MD, FACC*,*,
Steven V. Manoukian, MD, FACC ,
Ramin Ebrahimi, MD, FACC ,
Charles V. Pollack, MD ,
E. Magnus Ohman, MD, FACC||,
Michael J. Attubato, MD, FACC*,
Roxana Mehran, MD, FACC# and
Gregg W. Stone, MD, FACC#
* Division of Cardiology, Department of Medicine, New York University School of Medicine, New York, New York
Emory University School of Medicine, Atlanta, Georgia
University of California and the Greater Los Angeles VA Center, Los Angeles, California
Pennsylvania Hospital, Philadelphia, Pennsylvania
|| Duke University Medical Center, Durham, North Carolina
# Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York.

View larger version (37K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Subgroup Analyses: 30-Day End Points for Diabetic Patients by Treatment Group
The outcome data in subgroups, which are displayed as relative risk (RR) (solid squares) with 95% confidence interval (CI) (horizontal lines), are consistent with the data in the overall diabetic population for treatment with bivalirudin monotherapy versus heparin plus a glycoprotein IIb/IIIa inhibitor (GPI). CABG = coronary artery bypass graft; CKMB = creatine kinase isoenzyme MB fraction; CrCl = creatinine clearance; PCI = percutaneous coronary intervention.
|
|
|